Sanofi Completes Acquisition of Inhibrx, Inc.

Sanofi announces the completion of its acquisition of Inhibrx, Inc. (“Inhibrx”). The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline, underscoring the company’s commitment to pursuing differentiated and potential best-in-class medicines that build upon our existing strengths and capabilities. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing.

Read the full article: Sanofi Completes Acquisition of Inhibrx, Inc. //

Source: https://www.globenewswire.com/news-release/2024/05/30/2890833/0/en/Press-Release-Sanofi-completes-acquisition-of-Inhibrx-Inc.html

Scroll to Top